Bone mineral density in a cohort of transfusion-dependent β-thalassemia (TDT) patients
DOI:
https://doi.org/10.15218/zjms.2024.13Keywords:
BMD, TDT, Z-score, OsteoporosisAbstract
Background and objective: β-Thalassemia is a common inherited disease in this region. A considerable number of transfusion-dependent β-thalassemia (TDT) patients suffer bone problems. The objective of this study was to evaluate bone mineral density in TDT patients using dual-energy X-ray absorptiometry (DEXA) scan.
Methods: In this study, 53 TDT patients aged ≥10 years, together with 25 normal healthy individuals were enrolled. Their bone status was assessed using DEXA scan at lumber spine (L1-L4) and femoral neck. The effect of physical, biochemical, and hormonal characteristics on the bone mineral density (BMD) parameters were evaluated. BMD-Z score was used to assess the magnitude of bone disease.
Results: The mean age of the patients was 21.3±7.8 years with male to female ratio 1.4:1. The values BMD parameters were significantly lower in the patients compared to the normal group. The mean values of BMD Z-core among the patients at lumber spine and femoral neck were -2.95±1.07 and -1.51±1.02 respectively. Among the patients, osteoporosis was detected in 69.8% and 13.2% in lumber spine and femoral neck respectively. None of the normal individuals had osteoporosis. Patients’ age. body mass index (BMI) and parathyroid hormone level had a significant association with BMD Z-score (P <0.05).
Conclusion: Osteoporosis and osteopenia are extremely prevalent among our TDT patients. DEXA scan is an effective, non-invasive, and relatively inexpensive procedure for assessing bone status.
Metrics
References
Origa R. β-Thalassemia. Genetics in Medicine 2017; 19(6):609–19. https://doi.org/10.1038/gim.2016.173
Senol SP, Tiftik EN, Unal S, Akdeniz A, Tasdelen B, Tunctan B. Quality of life, clinical effectiveness, and satisfaction in patients with beta thalassemia major and sickle cell anemia receiving deferasirox chelation therapy. J Basic Clin Pharm 2016; 7(2):49–59. https://pubmed.ncbi.nlm.nih.gov/27057126
Bordbar M, Omrani GR, Haghpanah S, Saki F, Karimi M, Zekavat O. Bone mineral density in transfusion-dependent thalassemia patients and its associated factors in Southern Iran. Arch Osteoporos 2020; 15(1):148. https://doi.org/10.1007/s11657-020-00811-7
Gaudio A, Morabito N, Catalano A, Rapisarda R, Xourafa A, Lasco A. Pathogenesis of Thalassemia Major-associated Osteoporosis: A Review with Insights from Clinical Experience. J Clin Res Pediatr Endocrinol 2019; 11(2):110–7. https://doi.org/10.4274/jcrpe.galenos.2018.2018.0074
Singh K, Agarwal S, Shukla A, Gupta S. A Sequence Variation: 713-8delC in the Transforming Growth Factor Beta 1 Gene Polymorphism in Thalassemia Major Patients. J Clin Densitom 2014; 17(1):185–9. https://doi.org/10.1016/j.jocd.2013.04.004
Rossi F, Perrotta S, Bellini G, Luongo L, Tortora C, Siniscalco D, et al. Iron overload causes osteoporosis in thalassemia major patients through interaction with transient receptor potential vanilloid type 1 (TRPV1) channels. Haematologica 2014; 99(12):1876–84. https://doi.org/10.3324/haematol.2014.104463
Poggi M, Sorrentino F, Pugliese P, Smacchia MP, Daniele C, Equitani F, et al. Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years. Ann Hematol 2016; 95(5):757–63. https://doi.org/10.1007/s00277-016-2633-y
Wong P, Fuller PJ, Gillespie MT, Kartsogiannis V, Milat F, Bowden DK, et al. The effect of gonadal status on body composition and bone mineral density in transfusion-dependent thalassemia. Osteoporos Int 2014; 25(2):597–604. https://doi.org/10.1007/s00198-013-2454-y
Fung EB. The importance of nutrition for health in patients with transfusion-dependent thalassemia. Ann NY Acad Sci 2016; 1368(1):40–8. https://doi.org/10.1111/nyas.13003
Bordbar M, Omrani GR, Haghpanah S, Saki F, Karimi M, Zekavat O. Bone mineral density in transfusion-dependent thalassemia patients and its associated factors in Southern Iran. Arch Osteoporos 2020; 15(1):148. https://doi.org/10.1007/s11657-020-00811-7
Shamoon RP, Al-Allawi NAS, Cappellini MD, Di Pierro E, Brancaleoni V, Granata F. Molecular Basis of β-Thalassemia Intermedia in Erbil Province of Iraqi Kurdistan. Hemoglobin 2015; 39(3):178–83. http://dx.doi.org/10.3109/03630269.2015.1032415
Al-Allawi NAS, Hassan KMA, Sheikha AK, Nerweiy FF, Dawood RS, Jubrael J, et al. β-Thalassemia mutations among transfusion-dependent thalassemia major patients in Northern Iraq Mol Biol Int 2010; 2010. Article ID 479282, DOI :10.4061/2010/479282.
De Sanctis V, Soliman AT, Elsefdy H, Soliman N, Bedair E, Fiscina B, et al. Bone disease in β thalassemia patients: past, present and future perspectives. Metabolism 2018; 80:66–79. https://doi.org/10.1016/j.metabol.2017.09.012
Meena MC, Hemal A, Satija M, Arora SK, Bano S. Comparison of Bone Mineral Density in Thalassemia Major Patients with Healthy Controls. Adv Hematol 2015; 2015:e648349. https://doi.org/10.1155/2015/648349
AL Jadir SM, Jalal MZ, AL Ghreer MF, AL Hamdani MS, AL Omaree WR. Osteoporosis in Iraqi patients with thalassemia. Arthritis Res Ther 2012; 14(1):P4. https://doi.org/10.1186/ar3605
Hashemieh M, Azarkeivan A, Radfar M, Saneifard H, Hosseini-Zijoud SM, Noghabaei G, et al. Prevalence of Osteoporosis among Thalassemia Patients from Zafar Adult Thalassemia Clinic, Iran. Iran J Blood Cancer 2014; 6(3):6. https://www.researchgate.net/publication/289078453
Izadyar S, Fazeli M, Izadyar M, Salamati P, Gholamrezanezhad A. Bone mineral density in adult patients with major thalassaemia: Our experience and a brief review of the literature. Endokrynol Pol 2012; 63:264–9. https://www.researchgate.net/publication/230762968
Soliman A, De Sanctis V, Yassin M. Vitamin D Status in Thalassemia Major: an Update. Mediterr J Hematol Infect Dis 2013; 5(1):e2013057. https://doi.org/10.4084/MJHID.2013.057
M. Salih M, N. Al-Khero K. Bone mineral density in beta thalassemia syndrome in Mosul city. Ann Coll Med Mosul 2013; 39(2):160–5. https://doi.org/10.33899/mmed.2013.81272
Ansaf AI, Faraj SA, Mohammed RA. Bone mineral density in patients with thalassemia major, the experience of a single institute. Int J Res Pharm Sci 2021; 10;12(1):676–82.
Zadeh M, Hussain H, Al Faisal W, Muhasin M. Osteoporosis and Associated Factors among Thalassemia Patients Referred to Bone Mineral Density Screening -Dubai Hospital, 2014-2017. Clin Case Rep Rev 2017; 3. https://doi.org/10.15761/CCRR.1000373
Fung EB, Aguilar C, Micaily I, Haines D, Lal A. Treatment of vitamin D deficiency in transfusion-dependent thalassemia. Am J Hematol 2011; 86(10):871–3. https://doi.org/10.1002/ajh.22117
Ansari-Moghadam AR, Adineh H, Zareban I, Almasy Z, Maghsudlu M. Bone Mineral Density (BMD) and Chemical Biomarkers Among Patients with Thalassemia Major and Intermedia in Iran. Health Scope 2018; 7(4). https://doi.org/10.5812/jhealthscope.64137
El-Nashar M, Mortagy AK, El-Beblawy NMS, El-Gohary E, Kamel IM, Rashad M, et al. Parathyroid hormone in pediatric patients with β-thalassemia major and its relation to bone mineral density; a case-control study. Egypt J Med Hum Genet 2017; 18(1):75–8. https://doi.org/10.1016/j.ejmhg.2016.03.004
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Nigar Omar, Rawand P. Shamoon (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The copyright on any article published in Zanco J Med Sci is retained by the author(s) in agreement with the Creative Commons Attribution Non-Commercial ShareAlike License (CC BY-NC-SA 4.0).
